everyone Thank joining us. you, you Juli, and for thank
first Officer Adaptimmune's Chief call. us get as early joined in earnings I I'd officially started, welcome his Before Gavin Financial to like April. Gavin to Wood
the Looking quarter, us. began strongly year for the back at first
responses January, cancer. early are but they are we new platform In people These of T-cell announced tumor indications. responses, SPEAR for validation in a four our with
We deal are to from second sheet having XXXX, the balance the $XXX of our close half to Astellas offering added in million and public January. funded with into the
clinical followed during first trials screening the extent including evolving, sites. across our programs. was increases in on R&D the COVID-XX. clinical slowdown is data And across before full of all January our associated inevitable vary still COVID-XX announcement quarter the likely with by impact The The its to impact
implemented disease colleagues. the we've our of company, safety reduce of ensure spread. a As to risk together new want ways working to We the of
conducting in time enrolled for all on-site, critical trials, So manufacturing we're working T-cells clinical patients SPEAR research activities. our
those and full make who running operating as thank working at to our SPEAR have those from been of close to the continued can to working our have throughout our T-cells all ground who capacity I facilities Manufacturing with the improves. situation March. our has facilities we been in employees, that hit sure both want home
patients patients in optimistic will will be sites trials for related and a And cells manufacturing still reduced whom participate able be April during our pandemic May, in for manufactured at are care. non-COVID-XX We resume screened we're as clinical level. we've patients to and the the
medical formats will International or at been scientific continue you data delayed out to our meetings we Liver press on we ASCO have updates meetings. at and In to expectations Congress. August virtual April when and laid communicate switched now between and many for Although release issued the would see XXth, a ASGCT, these
program ASGCT. strides the our Earlier get this generation into cells, T-cells week, allogeneic at of timing required an progenitor of cells great receptor in T-cells We've the location made to we make including to engineering presented edits banks. from data stem the and T-cell for from
that from cells can products. are have engineered We cancer to as as functional cells clinic. in significant produce been T-cells progressing stem vitro in able kill the allogeneic our platform effectively autologous These our towards steps control targets engineered also from
SPEAR At sarcoma, synovial with from broad indications. from X Anderson T-cells ADP-AXMX, our a of well full data give patients targeting the from David summary as data of ASCO, including Cancer as generation will Hong This the more mature Phase provide Center presentation other first a an Dr. data with will trial trial, presentation MAGE-AX. MD of oral range
strength clinical with May that ASCO a oral of morning by a available online content The of press presentation validation acceptance be our an ASCO And of we will as is full day. ADP-AXMX update abstract release same this the will The program. XXth. of issue the
for We of Q&A. will in virtual be day also throughout available boot a XXth the ASCO the
Phase X trial. a ADP-AXMX learned We've the from lot
successfully learned expressed tumor responses is tumors to at targets against on of levels cancer high responses. MAGE-AX multiple MAGE-AX learned a We've MAGE-AX expressing have and and viable types. go trafficking can a results T-cell enough in the range that in in target We broader cells TCR that
our X radiation trial present the these as to track program targeting sub against both the information study SURPASS trials of medical well which of as our cancers build we're these a MAGE-AX this And cells used are of broad We've in generation include, assets range we of trial. XXXX. since in at Phase our testing out ADP-AXMX our conference from data half on CDX next to second
for soon patients the called SPEARHEAD-X. cancer. as trial program ADPA-AXMX and combination X neck a clinical PD-X Phase includes also with All possible. sites be This activated will with This as and be trial head inhibitor will
Committee was recently in treatment trial of adoption for the the EMA's for opinion of soft ADP-AXMX positive Medicinal Our Products sarcomas. acknowledged the designation, Orphan orphan by sarcoma for tissue SPEARHEAD-X a with this drug
XXXX FDA advanced drug In soft that clearly sarcomas. orphan improvements to and of tissue RMAT current the designation ADP-AXMX designation the offer then this QX had announced for demonstrated potential for substantial standard of we granted care treatment has the program. over
a believe of product in our position designations, strong three first U.S. these we're goal the achieve our XXXX. With we in launching in to
staff we capabilities commercial up add preparation ramping is towards and commercial our Our scale. develop key as
Finally, which that at April. Dr. And Conference we Sangro are dose third Spain are Navarra in we from International progressing our Bruno the August, present was delighted from from the ADP-AXAFP in delayed program cohort in liver data will University cancer. Clinic Liver
expansion SPEAR cohort to billion enroll XX the to up doses progressed T-cell. to of continue trial We this having
I in with years. past significant the As started and earlier, said most in our tumors the strong our validation multiple SPEAR solid five deal platform XXXX T-cell us of for
open to the up I'll call Operator? questions. Now
Company. [Operator Instructions] from Marc question Our comes Cowen first with Frahm and
now is line Your open.
